GRAIL

GRAIL, Inc. is a biotechnology firm dedicated to advancing innovations for detecting cancer at its earliest stages. Among its key offerings is Galleri, a screening test designed for individuals aged 50 and above who show no symptoms of the disease. GRAIL also offers DAC (Diagnostic Aid for Cancer), which assists in expediting the diagnostic process for patients where cancer is clinically suspected. Additionally, the company is actively engaged in the development of minimal residual disease (MRD) tests and various other post-diagnosis solutions. Established in 2015 with its headquarters in Menlo Park, California, GRAIL, Inc. previously operated as a subsidiary of Illumina, Inc.